119137 Adenosine A2A Receptor Agonist I, CGS 21680, Hydrochloride - CAS 124182-57-6 - Calbiochem

119137
가격을 검색할 수 없습니다
Minimum Quantity needs to be mulitiple of
가격 문의 추가 정보
()이 할인됨
 
가격 문의
재고 없음재고 없음
예상 출고 가능일 
단종품
제한된 수량 가능
재고여부 확인
    Remaining: will advise
      Remaining: will advise
      추천사항
      고객 서비스로 문의
      Contact Customer Service
      가격 및 재고 조회

      개요

      Replacement Information

      가격 및 재고여부

      카탈로그 번호 재고 정보패킹 포장 단위 가격(VAT 별도) 수량
      119137-5MGCN
      재고 정보 검색...
      재고 없음재고 없음
      예상 출고 가능일 
      단종품
      제한된 수량 가능
      재고여부 확인
        Remaining: will advise
          Remaining: will advise
          추천사항
          고객 서비스로 문의
          Contact Customer Service

          Glass bottle 5 mg
          가격 검색...
          가격을 검색할 수 없습니다
          Minimum Quantity needs to be mulitiple of
          가격 문의 추가 정보
          ()이 할인됨
           
          가격 문의
          Description
          OverviewA xanthin derivative that acts as a potent agonist of adenosine A2A receptors (Ki = 27 nM). Exhibits reduced affinity for A2B receptors (Ki = 67 nM), but offers greater selectivity over A1R (Ki = 290 nM) and A3R (88.8 µM). Exerts an anti-inflammatory effect during chronic inflammation and ameliorates the tissue damage associated with collagen-induced arthritis. Also shown to reduce CCR7 Protein Expression in THP1 macrophages. Shown to delay the progressive deterioration of motor performance and prevent a reduction in brain weight in murine model of Huntington's disease. Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.
          Catalogue Number119137
          Brand Family Calbiochem®
          SynonymsCGS-21680, CGS21680, 3-(4-(2-((6-amino-9-((2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-2-yl)amino)ethyl)phenyl)propanoic acid
          References
          ReferencesWillians, A. J., et al. 2012. Inflammation. 35, 614.
          Mazzon, E. et al. 2011. J Rheumatol. 38, 2119,
          Martire, A., et al. 2007. Neurosci Lett. 417, 78.
          Chou, S. Y., et al, 2005. Journ Neurochem. 93, 310.
          Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol.362 382.
          Phillis, J. W., et al. 1990.Brain Res. 509, 328.
          Product Information
          CAS number124182-57-6
          FormWhite solid
          FormulationSupplied as a hydrochloride salt.
          Hill FormulaC₂₃H₂₉N₇O₆ • HCl
          Chemical formulaC₂₃H₂₉N₇O₆ • HCl
          Structure formula ImageStructure formula Image
          Quality LevelMQ100
          Applications
          Biological Information
          Purity≥96% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Standard Handling
          Storage -20°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          Adenosine A2A Receptor Agonist I, CGS 21680, Hydrochloride - CAS 124182-57-6 - Calbiochem MSDS

          타이틀

          물질안전보건자료(MSDS) 

          Adenosine A2A Receptor Agonist I, CGS 21680, Hydrochloride - CAS 124182-57-6 - Calbiochem Certificates of Analysis

          TitleLot Number
          119137

          References

          참고문헌 보기
          Willians, A. J., et al. 2012. Inflammation. 35, 614.
          Mazzon, E. et al. 2011. J Rheumatol. 38, 2119,
          Martire, A., et al. 2007. Neurosci Lett. 417, 78.
          Chou, S. Y., et al, 2005. Journ Neurochem. 93, 310.
          Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol.362 382.
          Phillis, J. W., et al. 1990.Brain Res. 509, 328.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision14-November-2019 JSW
          SynonymsCGS-21680, CGS21680, 3-(4-(2-((6-amino-9-((2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-2-yl)amino)ethyl)phenyl)propanoic acid
          DescriptionA xanthin derivative that acts as a potent agonist of adenosine A2A receptors (Ki = 27 nM). Exhibits reduced affinity for A2B receptors (Ki = 67 nM), but offers greater selectivity over A1R (Ki = 290 nM) and A3R (88.8 µM). Exerts an anti-inflammatory effect during chronic inflammation and ameliorates the tissue damage associated with collagen-induced arthritis. Also shown to reduce CCR7 Protein Expression in THP1 macrophages. Shown to delay the progressive deterioration of motor performance and prevent a reduction in brain weight in murine model of Huntington's disease.
          FormWhite solid
          FormulationSupplied as a hydrochloride salt.
          Intert gas (Yes/No) Packaged under inert gas
          CAS number124182-57-6
          Chemical formulaC₂₃H₂₉N₇O₆ • HCl
          Structure formulaStructure formula
          Purity≥96% by HPLC
          SolubilityDMSO (100 mM)
          Storage -20°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesWillians, A. J., et al. 2012. Inflammation. 35, 614.
          Mazzon, E. et al. 2011. J Rheumatol. 38, 2119,
          Martire, A., et al. 2007. Neurosci Lett. 417, 78.
          Chou, S. Y., et al, 2005. Journ Neurochem. 93, 310.
          Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol.362 382.
          Phillis, J. W., et al. 1990.Brain Res. 509, 328.